Loading…
← CockpitCompetitor Analysis › 2041.HK Medcaptain Medical Technology Co. Ltd. Class HOpen in the cockpit ↗

Medcaptain Medical Technology Co. Ltd. Class H2041.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Mkt cap
$378M
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$117,980
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.7 pp
WACC 5.5%
Hurdle
-1 pp
Req g minus delivered
Close · HKDHK$5.72
1D-3.5%
1W-11.2%
1M-9.2%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %6.6%
52w lowhigh47.5% off high

What Medcaptain Medical Technology does

No business profile yet.

Medcaptain Medical Technology at a glance

Size Medcaptain Medical Technology (2041.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $378M, the 832nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.72 on 18 Nov 2026.

Growth Revenue grew 19.4% over the last twelve months (peer median +7.1%); the operating margin is 2.5% (peer median 12.2%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.8× (5th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points below its cost of capital (5.5% WACC).

Medcaptain Medical Technology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.94BHK$1.76BHK$1.52BHK$1.45BHK$1.07B
Revenue growth—+16%+5%+36%—
Gross profitHK$1.03BHK$893MHK$754MHK$720MHK$466M
EBITDAHK$189MHK$198MHK$18.8MHK$13.1M-HK$198M
Net incomeHK$10.4MHK$53.0M-HK$105M-HK$70.4M-HK$259M
Free cash flowHK$196MHK$104MHK$57.2M-HK$33.3MHK$16.8M
Capital expenditureHK$99.4MHK$107MHK$146MHK$99.7MHK$110M
Total debtHK$495MHK$455MHK$460MHK$604MHK$561M

Quarterly statements and history in the cockpit →

Medcaptain Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+20%+40%0×10×20×6051866748041830300562BWAY4736002022CVSBSCERS45887016096929688338MASS3002386881332041.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medcaptain Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%041830300562BWAY4588701609688338MASS2041.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Medcaptain Medical Technology is the large dot.

Medcaptain Medical Technology competitors and peer comparison

How Medcaptain Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medcaptain Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure2041.HKPeer medianRank in peer set
1-month return-9.2%-11.6%8th highest of 21
Distance from 52-week high-47.5%-43.6%6th lowest of 21
Revenue growth (TTM)+19.4%+7.1%6th highest of 21
Operating margin2.5%12.2%7th lowest of 21
EV / Sales1.5×3.8×5th cheapest of 21
Growth the price implies (Req g, 7 yrs)17.1%-4.2%5th most demanding of 14
Growth delivered (Del g)+18.1%+5.6%4th highest of 14
Hurdle (Req g minus delivered)-1.0 pp+1.8 pp7th least demanding of 14
ROIC minus cost of capital-3.7 pp+7.3 pp8th lowest of 20
EV / EBITDA15.2×8.1×3rd most expensive of 10
Net debt / EBITDA-0.5×-3.6×4th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%1.4×-10.3%+16.9%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%5.4×18.4%+4.4%
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%1.1×-12.7%-1.3%

Questions

Which companies are Medcaptain Medical Technology's closest peers?
The cockpit's peer set: Shanghai General Healthy Information & Technology (605186.SS), ACRO Biomedical (6748.TWO), InBody (041830.KS), Guangdong Transtek Medical Electronics (300562.SZ), Brainsway Ltd Sponsored ADR (BWAY), Taidoc Technology (4736.TW), Shanghai Kehua Bio-Engineering (002022.SZ), CapsoVision (CV).
Is Medcaptain Medical Technology expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 3.8×, 5th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -1 pp: the price already allows for a slowdown.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.